Wegovy Monitoring Schedule: Labs, Exams & Follow-Up Timeline

How Wegovy Works: The Mechanism Behind the Monitoring

Semaglutide 2.4 mg is a GLP-1 receptor agonist that mimics endogenous glucagon-like peptide-1, binding to receptors in the hypothalamus to reduce appetite and in the gastrointestinal tract to slow gastric emptying [1]. The drug's 165-hour half-life allows once-weekly dosing. In STEP-1 (N=1,961), participants on semaglutide 2.4 mg lost 14.9% of their body weight at 68 weeks compared with 2.4% in the placebo arm [2]. That degree of weight loss triggers metabolic shifts in glucose homeostasis, lipid metabolism, hepatic fat content, and renal hemodynamics, all of which require structured laboratory surveillance.

Because GLP-1 receptor agonists stimulate insulin secretion in a glucose-dependent manner, patients on concurrent sulfonylureas or insulin face hypoglycemia risk that must be tracked with serial glucose and HbA1c measurements [3]. The FDA prescribing information for Wegovy also carries a boxed warning about thyroid C-cell tumors observed in rodent studies, making thyroid monitoring a non-negotiable part of the clinical workflow [4]. Monitoring is not bureaucratic overhead. It is the clinical infrastructure that makes safe, sustained weight loss possible.

Baseline Labs Before the First Injection

Every patient should have a complete metabolic panel, HbA1c, fasting lipid panel, and TSH drawn before starting the 0.25 mg initiation dose. The complete metabolic panel captures fasting glucose, serum creatinine, eGFR, ALT, AST, and alkaline phosphatase in a single draw. These values establish the reference range against which all future results are compared.

The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines recommend that clinicians also obtain a fasting insulin level and calculate HOMA-IR at baseline to quantify insulin resistance [5]. For patients with a BMI of 30 or higher (or 27 or higher with at least one weight-related comorbidity), the AACE advises documenting waist circumference, blood pressure, and resting heart rate at the same visit. A baseline lipase level is optional but useful: it creates a reference point that can speed the workup if a patient later develops acute abdominal pain during dose escalation.

Dr. W. Timothy Garvey, lead author of the AACE obesity guidelines, has stated: "Baseline laboratory assessment is the foundation of safe pharmacotherapy. You cannot monitor what you have not measured" [5]. That principle applies with particular force to semaglutide, given its broad metabolic effects.

The Dose-Escalation Phase: Weeks 1 Through 16

Wegovy follows a 16-week titration from 0.25 mg to 2.4 mg, with dose increases every four weeks (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) [4]. Gastrointestinal side effects peak during this window. Nausea affected 44.2% of semaglutide-treated patients in STEP-1, and vomiting occurred in 24.8% [2]. While most GI symptoms are self-limiting, persistent vomiting or diarrhea can cause dehydration and acute kidney injury (AKI).

The FDA has received post-marketing reports of AKI in patients on GLP-1 receptor agonists, most commonly in patients who experienced significant GI fluid losses [4]. During dose escalation, clinicians should check a basic metabolic panel (BMP) at any visit where the patient reports more than three days of vomiting or diarrhea. Patients with a baseline eGFR between 30 and 59 mL/min/1.73 m² deserve a BMP at each dose step regardless of symptoms.

No routine mid-titration labs are required for patients with normal baseline renal function and mild or no GI symptoms. The first scheduled follow-up labs should occur four weeks after reaching the 2.4 mg maintenance dose.

Routine Monitoring at 3, 6, and 12 Months

Once a patient is stable on 2.4 mg weekly, the monitoring cadence follows a 3-6-12 rhythm for the first year. At each interval, draw HbA1c (even in non-diabetic patients, because semaglutide improves glycemic markers and the trajectory matters), a fasting lipid panel, and a comprehensive metabolic panel.

Three-Month Visit

The 3-month mark typically falls 8 weeks after maintenance-dose stabilization. By this point, patients in STEP-1 had achieved roughly 6% body-weight loss [2]. Lab priorities include:

• HbA1c or fasting glucose to assess glycemic improvement
• ALT and AST to track hepatic fat reduction (semaglutide reduced liver fat by 8.0 percentage points in the STEP-1 hepatic sub-study [6])
• Serum creatinine and eGFR if baseline renal function was borderline
• Blood pressure and resting heart rate (semaglutide increased resting heart rate by 1 to 4 beats per minute in pooled STEP data [4])

Six-Month Visit

At 6 months, the Endocrine Society recommends evaluating whether the patient has achieved at least 5% total body-weight loss [7]. If not, the prescriber should reassess adherence, diet, and whether adjunctive therapy is appropriate. Labs at this visit repeat the 3-month panel and add a repeat fasting lipid profile. In STEP-1, LDL cholesterol dropped by 3.1% and triglycerides fell by 12.4% at 68 weeks in the semaglutide group [2]. Confirming lipid improvement at month 6 may allow deprescribing a statin in selected patients.

Twelve-Month Visit

The 12-month labs mirror the 6-month panel with the addition of a repeat TSH. Although no causal link between semaglutide and thyroid dysfunction has been established in humans, the boxed warning for C-cell tumors in rodents makes annual thyroid surveillance a prudent default [4]. Dr. Robert Kushner, co-investigator on the STEP trials, has noted: "Annual thyroid function testing in patients on GLP-1 receptor agonists is low-cost, low-risk, and closes a surveillance gap that most clinicians would regret leaving open" [8].

Renal Monitoring: Who Needs Extra Attention

Patients entering Wegovy therapy with CKD stage 3 or higher (eGFR <60 mL/min/1.73 m²) require intensified renal surveillance. The FLOW trial (N=3,533), which studied semaglutide 1 mg in patients with type 2 diabetes and CKD, demonstrated a 24% reduction in the composite kidney endpoint, but also flagged that GI-related dehydration was the primary driver of AKI events [9]. In the chronic weight-management population, where the dose is 2.4 mg and GI side effects are more prevalent, this risk is amplified.

For these patients, a BMP should be drawn at every dose-escalation step and at 1, 3, 6, 9, and 12 months on maintenance. A rise in serum creatinine of 0.3 mg/dL or more from baseline, or a drop in eGFR of 25% or more, should trigger temporary dose reduction and IV hydration assessment before restarting. The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guidelines endorse GLP-1 receptor agonists for CKD patients with obesity but stress the need for "proactive renal monitoring during titration and any intercurrent illness involving fluid loss" [10].

Gallbladder Surveillance: Symptoms Over Screening

Rapid weight loss from any cause increases gallstone formation. In the STEP trials, cholelithiasis occurred in 1.6% of semaglutide-treated patients versus 0.7% on placebo, and cholecystitis requiring cholecystectomy occurred in 0.4% versus 0.1% [2][4]. Routine abdominal ultrasound screening is not recommended because the detection of asymptomatic gallstones does not change management. Instead, educate patients to report right upper quadrant pain, post-prandial bloating, or referred right shoulder pain promptly.

If symptoms develop, obtain a right upper quadrant ultrasound and hepatobiliary labs (total bilirubin, direct bilirubin, alkaline phosphatase, GGT). The typical onset window is 4 to 9 months after treatment initiation, coinciding with the period of most rapid weight loss. Patients losing more than 1.5 kg per week for more than four consecutive weeks face the highest risk. Weight-loss velocity, not drug exposure alone, drives gallstone formation.

Pancreatitis: When to Check Lipase

Acute pancreatitis is listed as a warning in the Wegovy prescribing information, though the absolute incidence is low. In pooled STEP data, pancreatitis events were numerically higher in the semaglutide group but did not reach statistical significance [4]. Routine lipase screening in asymptomatic patients is not indicated because elevated lipase without symptoms is common in patients on GLP-1 receptor agonists and does not predict clinical pancreatitis [11].

Check serum lipase and amylase only when a patient presents with acute epigastric pain radiating to the back, especially if accompanied by nausea or vomiting. A lipase level exceeding three times the upper limit of normal, combined with consistent symptoms, warrants Wegovy discontinuation and standard pancreatitis management. Patients with a personal history of pancreatitis should be monitored with a lower threshold for lipase testing, though prior pancreatitis is not an absolute contraindication to semaglutide therapy per the FDA label [4].

Thyroid Monitoring and the C-Cell Tumor Warning

The boxed warning on Wegovy states that semaglutide caused thyroid C-cell tumors in rodents at clinically relevant exposures [4]. No causal relationship has been established in humans. Large pharmacovigilance analyses of GLP-1 receptor agonist use, including a 2023 meta-analysis of over 60,000 patient-years of exposure, found no statistically significant increase in medullary thyroid carcinoma (MTC) [12].

Wegovy is absolutely contraindicated in patients with a personal or family history of MTC or multiple endocrine neoplasia type 2 (MEN 2). For all other patients, check TSH at baseline and annually. Calcitonin screening is not recommended routinely because the positive predictive value in the general population is too low to justify the false-positive workup cascade [7]. If a thyroid nodule is palpated on clinical exam, obtain a thyroid ultrasound and serum calcitonin. The Endocrine Society position is that "physical examination of the thyroid at each clinical visit is a reasonable, low-burden surveillance strategy for patients on long-term GLP-1 receptor agonist therapy" [7].

Cardiovascular and Metabolic Markers: Beyond Weight

Semaglutide 2.4 mg reduced systolic blood pressure by 6.2 mmHg relative to placebo in STEP-1 [2]. The SELECT trial (N=17,604), which tested semaglutide 2.4 mg in patients with established cardiovascular disease but without diabetes, showed a 20% reduction in the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke over a median 39.8 months [13]. These cardiovascular benefits make serial blood-pressure measurement and lipid tracking clinically meaningful, not just administrative.

At every monitoring visit, record blood pressure, resting heart rate, and waist circumference. A sustained resting heart rate increase above 100 bpm warrants an ECG and clinical reassessment, though most patients experience increases of only 1 to 4 bpm [4]. For patients with pre-existing atrial fibrillation or heart failure, coordinate monitoring with cardiology.

Long-Term Monitoring Beyond Year One

After the first year, stable patients with normal labs can transition to every-6-month or annual monitoring. The minimum annual panel includes HbA1c, fasting lipids, CMP, and TSH. Patients who discontinue Wegovy should be monitored for weight regain: in the STEP-4 extension, participants who switched from semaglutide to placebo at week 20 regained 6.9% of body weight by week 68 [14]. Post-discontinuation, check metabolic markers at 3 and 6 months to catch rebound dyslipidemia or glycemic deterioration early.

Patients on Wegovy for two years or longer should also receive periodic screening for nutritional deficiencies. Reduced caloric intake over extended periods can deplete iron, vitamin B12, vitamin D, and folate stores. A CBC with differential and 25-hydroxyvitamin D level once yearly is a low-cost addition that prevents avoidable complications.

The final clinical anchor: no monitoring schedule replaces the patient-clinician conversation. Every lab draw is an opportunity to reassess treatment goals, medication tolerance, and the broader metabolic picture. The protocol outlined above provides the structure. The clinician provides the judgment.